Sarizotan
As of the edition of 20 October 2026, Sarizotan is a small molecule: stopped in 2020; acts on DRD2, DRD3 and DRD4 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Small molecule
- Registered trials
- 6, 2 stopped early
- Disease areas
- Nervous system; Inherited and neonatal; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product8 company-target rows are on route A because of Sarizotan.
See the 8 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 3 | 2 | 0 | 1 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2002 to now |
| Newron Pharmaceuticals | Lead sponsor of trials | 2016 to now |